{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:49Z","timestamp":1787071069743,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The purpose of the study was to analyze the survival outcomes and toxicities in squamous cell carcinoma anal canal treated with definitive chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Retrospective analysis of 51 patients with squamous cell carcinoma anal canal treated with chemoradiotherapy was done. Data were collected and analyzed for disease-free survival (DFS), colostomy-free survival (CFS), overall survival (OS), and acute\/late toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of total 51 patients, only 44 patients had a follow-up of more than 36 months and were analyzed. After a median follow-up of 46 months (range 10\u201368 months), the 3-year DFS was 73.9%. Three patients developed locoregional recurrence, while one patient developed distant metastasis. At 3-year OS rate was 77%. Out of 44 patients, six patients lost to follow\u2013up, while two patients died due to progressive disease and two due to noncancer causes. 3-year CFS rate was 59%. Most common grade &gt;3 acute toxicities were skin reactions in nine (18%), followed by hematological in eight (16%) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Definitive chemoradiotherapy in anal canal results in good oncological outcomes with sphincter preservation. No severe treatment-related toxicities were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_979_20","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:05:12Z","timestamp":1671156312000},"page":"S405-S409","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal"],"prefix":"10.4103","volume":"18","author":[{"given":"Viney","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Badola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Nautiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-42-20241021","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/j.clcc.2018.10.001","article-title":"Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016","volume":"18","author":"Guren","year":"2019","journal-title":"Clinical Colorectal Cancer"},{"key":"R3-42-20241021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s13187-019-01503-8","article-title":"Knowledge of anal cancer, anal cancer screening, and HPV in HIV-positive and high-risk HIV-negative women","volume":"35","author":"Wells","year":"2020","journal-title":"J Cancer Educ"},{"key":"R4-42-20241021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00001622-200007000-00011","article-title":"Anal carcinoma: Histology, staging, epidemiology, treatment","volume":"12","author":"Ryan","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"R5-42-20241021","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.canrad.2006.09.116","article-title":"[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]","volume":"10","author":"Deniaud-Alexandre","year":"2006","journal-title":"Cancer Radiother"},{"key":"R6-42-20241021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-11-55","article-title":"Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma","volume":"11","author":"Zampino","year":"2011","journal-title":"BMC Cancer"},{"key":"R7-42-20241021","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3748\/wjg.v21.i8.2294","article-title":"Anal cancer treatment: Current status and future perspectives","volume":"21","author":"Ghosn","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R8-42-20241021","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: A preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"R10-42-20241021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R12-42-20241021","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0360-3016(89)90520-8","article-title":"Radiotherapy for anal cancer: Experience from 1979-1987","volume":"17","author":"Hughes","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-42-20241021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"R14-42-20241021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14216\/kjco.16007","article-title":"Oncologic outcomes of squamous cell carcinoma of the anal canal after chemoradiation therapy","volume":"12","author":"Lim","year":"2016","journal-title":"Korean Journal of Clinical Oncology"},{"key":"R15-42-20241021","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"R16-42-20241021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3857\/roj.2013.31.1.25","article-title":"Chemoradiotherapy in squamous cell carcinoma of the anal canal: A single institution experience","volume":"31","author":"Kim","year":"2013","journal-title":"Radiat Oncol J"},{"key":"R17-42-20241021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1748-717X-9-124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma","volume":"9","author":"Thind","year":"2014","journal-title":"Radiat Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_979_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:03Z","timestamp":1787067663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_979_20"}},"subtitle":["A single-institution experience"],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":14,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_979_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}